Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12228161 | 0.89 | BCHE (0.72) | BCHECYP2D6 | |
| SCHEMBL5947302 | 0.88 | MAPK1 (0.56) | BCHECYP2D6ROCK2ROCK1CYP3A4 | |
| SCHEMBL5947308 | 0.86 | BCHE (0.59) | BCHECYP2D6SMN1; SMN2MAPK1KCNH2 | |
| SCHEMBL5947547 | 0.85 | BCHE (0.59) | BCHECYP2D6SMN1; SMN2MAPK1KCNH2 | |
| SCHEMBL5947825 | 0.85 | BCHE (0.73) | BCHECYP2D6SMN1; SMN2 | |
| SCHEMBL5947204 | 0.85 | BCHE (0.59) | BCHECYP2D6SMN1; SMN2KCNH2 | |
| SCHEMBL5947391 | 0.85 | BCHE (0.73) | BCHECYP2D6SMN1; SMN2MEN1HTT | |
| SCHEMBL5947471 | 0.85 | BCHE (0.58) | BCHECYP2D6SMN1; SMN2KCNH2 | |
| SCHEMBL5947161 | 0.85 | SMN1; SMN2 (0.61) | BCHECYP2D6CYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL5947418 | 0.85 | BCHE (0.58) | BCHECYP2D6CYP3A4SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | claimed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | BCHE 763/4885CYP2D6 143/4885ROCK2 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.